Coronis Neurosciences

Neurocognitive and Neurodegenerative Therapies

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
Coronis Neurosciences
02/07/2022
NeuroPharmacology | NeuroBioTechnology
Biotechnology & Biopharmaceutical
Clinical use (of cognitive, psychological, psychiatric, inc. early diagnosis)
Biochemical: pharmacological drugs (Developing drugs)
01/01/2014
"1-10"

Coronis Neurosciences is a specialty pharmaceutical company focused on the development of therapies for neurocognitive and neurodegenerative disorders. Coronis owns a pipeline of several clinical- and preclinical-stage molecules and strives to build value through the clinical development of proprietary formulated drugs.



The company's pipeline includes CP201, its leading drug, developed to treat ADNP syndrome. CP201 is a trans-nasally delivered peptide (NAP) developed for the treatment of ADNP syndrome in children. ADNP syndrome, an autism spectrum disorder, is a rare neurogenetic disease caused by de novo mutations in the ADNP gene.



Coronis also develops CP101, a drug to treat cognitive impairment associated with schizophrenia (CIAS) using a proprietary new small peptide.